# A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

> **NCT05644977** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 17 (actual)

## Conditions studied

- Healthy Participants
- Alzheimer's Disease Dementia

## Interventions

- **DRUG:** Emraclidine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05644977
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-02
- **Primary completion:** 2025-04-14
- **Final completion:** 2025-04-14
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2025-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05644977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05644977, "A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05644977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*